

FOR IMMEDIATE RELEASE

ADVANTAGE INVESTS IN SINGULEX FINANCING ROUND

Biotech company has raised nearly \$11 million

ST. LOUIS, December 20, 2006—Advantage Capital Partners has invested \$350,000 in Singulex Inc., a biotech company utilizing single-molecule detection technology to enable disease understanding and research, as part of the company's most recent fundraising. Including Advantage, investors such as Fisk Ventures, Prolog Ventures, GE Capital and Bridge Bank and others have provided nearly \$11 million in Series C funding and debt financing.

The funds will enable Singulex to meet the target commercialization launch of the Erenna System in 2007. A digital single-molecule detection program, the Erenna System helps researchers understand how proteins and protein variants interact in normal and disease processes.

“Establishing normal protein levels has presented serious hurdles in the advancement of diagnostics for therapy selection, disease diagnosis and preclinical and clinical evaluation of therapeutic candidates,” said Philippe Goix, chief executive officer and president of Singulex. “The Erenna System is engineered to enable life science research to obtain quantitative information on normal and abnormal protein levels in any type of biological sample.”

Singulex is partnering with pharmaceutical companies in key pilot studies where Erenna technology is being used to monitor biomarkers in clinical samples and to generate clinically useful information. The system also has been installed at a molecular diagnostic company site to aid in biomarker assay discovery and validation on clinical specimens.

“Singulex offers a unique, proven technology for measuring extremely small quantities of proteins or other single molecules with high precision and low sample size requirements,” said Jeremy Degenhart, Advantage vice president. “The capabilities of the system, coupled with its broad applicability and the company's strategic biopharmaceutical partnerships, position Singulex for solid growth.”

Advantage's investment was made in connection with the federal New Markets Tax Credit (NMTC) program. With more than \$100 million in New Markets investments to date, Advantage is a leading participant in this innovative federal program that encourages investment in targeted communities.

About Singulex

Singulex (www.singulex.com) develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme

sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's leading digital molecule detection platform, the Erenna™ BioAssay System, which will be commercially available in the first half of 2007.

About Advantage Capital Partners

Advantage Capital Partners (www.advantagecap.com) is a private equity firm focused on investing in promising companies in connection with federal, state and local economic development efforts. With offices and partners in ST. Louis, New Orleans, New York and other cities, Advantage has raised more than \$750 million in institutional venture capital since 1992 and invested in companies located in geographic areas underserved by traditional venture capital.